Incyte (INCY) Q4 2025 earnings review
Strong Finish to 2025, but Opzelura Slowdown Looms
Incyte delivered a robust Q4 with Total Revenue growing 28% YoY to $1.51B, significantly outpacing the 16% growth seen in Q2. The bottom line also surged, with Non-GAAP Net Income up 31%. The star of the quarter was the new launch Niktimvo, which continues to beat expectations. However, the narrative is mixed: while the core business is accelerating, 2026 guidance suggests a sharp deceleration for Opzelura, the company's primary growth engine outside of oncology, projecting mid-teens growth versus 33% in 2025.
🐂 Bull Case
The GVHD drug Niktimvo is outperforming. Sales ramped from $14M in Q1 (partial) to $56M in Q4. FY25 total of $152M establishes it as a major third pillar alongside Jakafi and Opzelura.
Despite maturity, Jakafi grew 7% in Q4 and 11% for FY25, beating the narrative of stagnation. With Jakafi XR pending approval (mid-2026 launch), the franchise has defenses against generic erosion.
🐻 Bear Case
Guidance implies Opzelura growth will slow dramatically from 33% in FY25 to ~13.5% in FY26. This raises concerns about the ceiling in Atopic Dermatitis and Vitiligo markets.
The company paused development of ruxolitinib cream for Prurigo Nodularis (PN) after FDA feedback required an additional study. This removes a near-term label expansion opportunity.
⚖️ Verdict: 🟢
Bullish. While the Opzelura guidance is conservative, the operational execution is excellent. Accelerating topline growth, a successful third product launch (Niktimvo), and expanding margins outweigh the dermatology slowdown risks.
Key Themes
Niktimvo Becomes a Star
Accelerating. Niktimvo generated $56M in Q4, up 22% sequentially from Q3. In its launch year, it delivered $152M, rapidly validating the asset in Chronic GVHD. It has effectively diversified the revenue base, reducing reliance on Jakafi.
Opzelura Growth Wall
Decelerating. Opzelura grew 28% in Q4, down from 35% in Q3. More concerning is FY26 guidance of $750-790M, implying only ~13.5% YoY growth at the midpoint. This is a stark contrast to the +33% growth achieved in FY25, suggesting the easy gains in the US AD/Vitiligo market are gone.
Ruxolitinib Cream PN Program Paused
Reversing. Following FDA feedback requiring an additional clinical study, Incyte decided to pause development of ruxolitinib cream for Prurigo Nodularis (PN). While the oral povorcitinib program in PN continues, this kills the near-term expansion opportunity for the topical franchise.
Jakafi Franchise Durability
Stable. The core Jakafi franchise grew 7% in Q4 to $828M. Importantly, FY26 guidance projects further growth to ~$3.25B. Management also submitted the response for Jakafi XR (extended release), with a decision expected in mid-2026. This extension strategy is critical for defending revenue through the end of the decade.
Operating Leverage Returns
Improving. After a messy FY24 due to the Escient acquisition, profitability has normalized. Q4 Non-GAAP Net Income was $368M (24% margin) vs $281M (24% margin) a year ago. FY25 Non-GAAP Net Income reached $1.37B, up dramatically from $228M in FY24.
Other KPIs
Beat expectations and accelerated to 28% YoY growth, driven by a $100M milestone payment and 20% growth in net product revenues.
Strong balance sheet, up from $2.2B at the end of 2024. This provides ample firepower for BD or buybacks, although no specific buyback activity was highlighted in Q4.
Accelerating. Combined revenue from Iclusig, Monjuvi, Niktimvo, Pemazyre, and Zynyz is becoming substantial. Niktimvo alone contributed $56M.
Guidance
Decelerating. The midpoint implies ~11.5% YoY growth vs 20% in FY25. While double-digit growth is healthy, it represents a slowdown as the law of large numbers affects Opzelura and Jakafi.
Stable. Implies ~5% growth at the midpoint ($3.245B) vs FY25's $3.09B. This confirms Jakafi is a mature cash cow growing at GDP+ rates.
Decelerating. Midpoint ($770M) implies ~13.5% growth. This is a significant step down from the 33% growth delivered in FY25 ($678M). Reasons likely include saturation in current indications and competition.
Accelerating. Comparing to FY25 actuals for this basket (Iclusig+Pemazyre+Monjuvi+Niktimvo+Zynyz ~= $485M), this guidance implies massive growth of ~73%. *Note: This basket likely includes new launches or expanded definitions not fully aligned with Q4 reporting, or assumes massive ramp in Niktimvo/Monjuvi.*
Key Questions
Opzelura Deceleration Drivers
Guidance implies Opzelura growth slows to ~13% next year. Is this driven by formulary pressure, patient saturation, or competitive headwinds in Atopic Dermatitis?
Hem/Onc Guidance Delta
The Hem/Onc guidance of $800-880M suggests a near doubling of that portfolio's revenue. Does this assume a specific steep ramp for Niktimvo, or are there other major launches baked into this number?
Cash Usage Strategy
With cash swelling to $3.6B, what is the priority for capital allocation between M&A (given the recent pause on internal assets like PN cream) and shareholder returns?